Statements of Cash Flows - USD ($)	9 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (6,749,317)	$ (11,571,963)
Adjustments to reconcile net loss to net cash used in operating activities
Preferred shares issued as compensation	175,200	174,259
Loss on issuance of preferred shares for accounts payable- related party	0	142,669
Common shares issued as compensation and for services	137,288	290,250
Warrants granted to Scientific Advisory Board	4,951	3,885
Depreciation	522,172	518,536
Amortization of loan origination fees	18,013	11,463
Amortization	6,202	6,204
Change in fair value of derivative liabilities	0	5,845,313
Loss on disposal of property and equipment	2,026	0
Write-off of deferred financing costs	12,190	0
Gain on warrant settlement	0	(614,494)
Changes in operating assets and liabilities:
Prepaid expenses	180,988	93,615
Other assets	10,158	11,688
Accounts payable	(282,492)	152,281
Accounts payable - related party	21,495	4,372
Accrued expenses	(45,012)	(25,313)
NET CASH USED IN OPERATING ACTIVITIES	(5,986,138)	(4,957,235)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(154,122)	(4,139)
NET CASH USED IN FINANCING ACTIVITIES	(154,122)	(4,139)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of common stock	16,563,697	7,457,575
Proceeds from note payable -related party	0	1,100,000
Payment of note payable - related party	(1,100,000)	0
Proceeds from loan payable	0	0
Payment of loan payable	(132,513)	(45,878)
NET CASH PROVIDED BY FINANCING ACTIVITIES	15,331,184	8,511,697
NET CHANGE IN CASH AND CASH EQUIVALENTS	9,190,924	3,550,323
Cash and cash equivalents at beginning of period	13,708,594	2,555,207
Cash and cash equivalents at end of period	22,899,518	6,105,530
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:
Interest paid	3,171	0
Non-cash Financing and Investing Activities:
Directors and Officers Insurance Financed Through loan	235,476	155,173
Cashless exercise of warrants reclassed from warrant liability to common stock	0	1,153,881
Series A preferred stock issued for accounts payable-related party	0	250,000
Series A preferred stock issued for loan origination fee	0	39,301
Common stock issued to settle accounts payable	$ 0	$ 52,000